Head & Neck Cancers

Micvotabart pelidotin produced a 36% confirmed ORR and a 6.2-month median PFS in pretreated recurrent/metastatic head and neck squamous cell carcinoma.

JBS-003 will be evaluated in an ongoing phase 3 trial designed to determine whether investigators can identify patients who can safely receive less radiation.

Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.

The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.

The HER2-directed ADC produced confirmed responses across both biomarker-defined cohorts of advanced salivary gland carcinoma.

Neoadjuvant PD-1–based immunotherapy plus chemotherapy produced pCRs across 3 cohorts in resectable locally advanced HNSCC.

PDS Biotechnology will prioritize the IL-12 immunocytokine PDS0301 in metastatic colorectal cancer and pursue a partnership strategy for PDS0101.

Dostarlimab monotherapy produced a 27% response rate in PD-L1–positive recurrent/metastatic head and neck squamous cell carcinoma

Low PD-L1 expression and node-negative status identified oral cancer patients most likely to benefit from neoadjuvant leukocyte interleukin injection.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA has granted priority review to subcutaneous amivantamab and hyaluronidase-lpuj for adults with recurrent or metastatic head and neck cancer.

Leukocyte interleukin injection improved OS in patients with oral cancer expressing low tumor PD-L1 levels.

Laurence J. DiNardo, MD, FACS, discusses ctDNA testing in head and neck cancers, advancements in targeted therapies, and multidisciplinary collaboration.

Alpha DaRT plus pembrolizumab produced responses in all evaluable older patients with PD-L1–positive recurrent/metastatic head and neck cancer.

Roswell Park Comprehensive Cancer Center investigators will deliver 21 presentations at the AHNS 12th International Conference on Head and Neck Cancer.

Trastuzumab deruxtecan did not meet the prespecified efficacy criterion in HER2-low salivary gland carcinoma, though responses were observed in salivary duct carcinoma.

The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.

Neoadjuvant and adjuvant pembrolizumab improved EFS across surgical outcome subgroups in resectable head and neck squamous cell carcinoma.

Izalontamab brengitecan has been approved in China for recurrent/metastatic NPC following disease progression on chemotherapy and PD-1/PD-L1 inhibition.

Ficerafusp alfa plus pembrolizumab generated a 54% ORR and 21.7-month median DOR in first-line HPV-negative recurrent or metastatic HNSCC.

Experts highlight the most interesting and potentially paradigm-shifting head and neck cancer data to come out of the 2026 ASCO Annual Meeting.

Sintilimab plus adjuvant capecitabine did not improve 2-year PFS outcomes vs capecitabine alone in NPC with suboptimal response to induction chemotherapy.

Ultra-low-dose nivolumab plus oral metronomic chemotherapy cut the risk of death by 43% versus paclitaxel-carboplatin in first-line platinum-sensitive recurrent or metastatic HNSCC.

Bispecific antibodies and the latest proton therapy techniques are taking center stage in the treatment of patients with head and neck cancers.